Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Discovery & Development Drug Discovery

Putting the Brakes on Inflammation

Geographic atrophy (GA) affects millions of patients worldwide and is characterized by the degradation of the retina following inflammasome-mediated events in the eye. Despite the challenges the disease presents, treatment options are scarce. But new research points to Kamuvudines – molecules that inhibit the inflammatory behavior of the innate immune system – in preventing retinal degradation in GA patients (1).

“Kamuvudines are modified derivatives of nucleoside reverse transcriptase inhibitors (NRTIs) – a class of anti-HIV drug,” says Jayakrishna Ambati, co-founder of Inflammasome Therapeutics and senior author of the study. “They block retinal cell death mediated by amyloid beta molecules.” Kamuvudines are less toxic than traditional NRTIs, making them suitable for long-term use.

The team is also exploring the potential of Kamuvudines in treating other inflammasome-mediated conditions, such as multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease. Ambati says, “Kamuvudines have broad applications. Using them, we have an opportunity to make a difference to the many patients who live with debilitating diseases that have previously been difficult to treat.”

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1.  S Narendran et al, Signal Transduction and Targeted Therapy (2021). https://doi.org/10.1038/s41392-021-00537-z
About the Author
Maryam Mahdi

Deputy Editor

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register